The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India
Background: Monoclonal antibodies have gained attention in developing countries owing to its benefits portrayed by few clinical trials. However, no studies until now have been undergone in India. Methods: A retro-prospective comparative observational study was conducted in symptomatic COVID19 patien...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | Clinical Epidemiology and Global Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213398422000070 |
| _version_ | 1811333018075267072 |
|---|---|
| author | Aneesh Puthiyedath Joy Anitha Theresa Augustine Mohammed Salim Karattuthodi Jaffer Chalil Parambil Dilip Chandrasekher P. Danisha Linu Mohan Panakkal Madhav A. Joshi K.T. Azharul Haque Irshad K. Mohammed Izudheen Shadia Badaruddeen Riya Sara John Sarath Murali Ardhra Rose Thomas Fathimath Sahla Shahir Ahmed KV. Ahmed Unni Raseel Omar Ahmed Shinu Cholamugath |
| author_facet | Aneesh Puthiyedath Joy Anitha Theresa Augustine Mohammed Salim Karattuthodi Jaffer Chalil Parambil Dilip Chandrasekher P. Danisha Linu Mohan Panakkal Madhav A. Joshi K.T. Azharul Haque Irshad K. Mohammed Izudheen Shadia Badaruddeen Riya Sara John Sarath Murali Ardhra Rose Thomas Fathimath Sahla Shahir Ahmed KV. Ahmed Unni Raseel Omar Ahmed Shinu Cholamugath |
| author_sort | Aneesh Puthiyedath Joy |
| collection | DOAJ |
| description | Background: Monoclonal antibodies have gained attention in developing countries owing to its benefits portrayed by few clinical trials. However, no studies until now have been undergone in India. Methods: A retro-prospective comparative observational study was conducted in symptomatic COVID19 patients to evaluate the impact of Casirivimab and Imdevimab antibody cocktail in the high-risk population. Through an extensive data retrieval for 6 months, 152 samples were documented and sorted into test (Casirivimab and Imdevimab treated patients, n = 79) and control (Non- Casirivimab and Imdevimab treated individuals, n = 73) subsets. The research had two phases; first, estimation of mechanical ventilation and high flow oxygen requirement and mortality in samples amidst the treatment, and second was the post COVID19 patients' feedback through validated (Cronbach's alpha coefficient = 0.7) questionnaire that evaluated their health and vaccination status, and treatment satisfaction. Results: We noticed lesser requisite for mechanical ventilation (6.3%; p < 0.001), high flow oxygen (5.1%; p < 0.001) and no death during Casirivimab and Imdevimab therapy. Meanwhile, non-vaccinated test groups were not on mechanical ventilation and those fully immunized seldom entailed high flow oxygen (test, 6.3%; control, 41.9%, p < 0.01). On evaluating the post COVID19 status of each patient in the study, 90.1% of the test samples were healthy and 97.2% were satisfied with the treatment than those in control group. Conclusions: Casirivimab and Imdevimab regimen was clinically beneficial for high risk COVID19 patients than those treated without the antibody cocktail. |
| first_indexed | 2024-04-13T16:45:50Z |
| format | Article |
| id | doaj.art-a51211d08f7343588c9f5c164566c949 |
| institution | Directory Open Access Journal |
| issn | 2213-3984 |
| language | English |
| last_indexed | 2024-04-13T16:45:50Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Epidemiology and Global Health |
| spelling | doaj.art-a51211d08f7343588c9f5c164566c9492022-12-22T02:39:05ZengElsevierClinical Epidemiology and Global Health2213-39842022-03-0114100967The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in IndiaAneesh Puthiyedath Joy0Anitha Theresa Augustine1Mohammed Salim Karattuthodi2Jaffer Chalil Parambil3Dilip Chandrasekher4P. Danisha5Linu Mohan Panakkal6Madhav A. Joshi7K.T. Azharul Haque8Irshad K. Mohammed Izudheen9Shadia Badaruddeen10Riya Sara John11Sarath Murali12Ardhra Rose Thomas13Fathimath Sahla14Shahir Ahmed KV. Ahmed Unni15Raseel Omar Ahmed16Shinu Cholamugath17Dept. of General Medicine, KIMS Al Shifa Super-Specialty Hospital, IndiaIMY 1, Aster, Wayanad, IndiaDept. of Pharmacy Practice, Al Shifa College of Pharmacy, India; Corresponding author. Dept. of Pharmacy Practice, Al Shifa College of Pharmacy, Kerala, 679325, India.Dept. of General Medicine, KIMS Al Shifa Super-Specialty Hospital, IndiaDept. of Pharmacy Practice, Al Shifa College of Pharmacy, IndiaDept. of Pharmacy Practice, Al Shifa College of Pharmacy, IndiaDept. of Pharmacy Practice, Al Shifa College of Pharmacy, IndiaDept. of General Medicine, KIMS Al Shifa Super-Specialty Hospital, IndiaDept. of Pulmonology, KIMS Al Shifa Super-Specialty Hospital, IndiaDept. of Pulmonology, KIMS Al Shifa Super-Specialty Hospital, IndiaDept. of Pharmacy Practice, Al Shifa College of Pharmacy, IndiaDept. of Pharmacy Practice, Al Shifa College of Pharmacy, IndiaDept. of Pharmacy Practice, Al Shifa College of Pharmacy, IndiaMedical Writer Intern, Ostum Global Medicomarketing, IndiaDept. of Pharmacy Practice, Al Shifa College of Pharmacy, IndiaDept. of Pharmacy Practice, Al Shifa College of Pharmacy, IndiaHealthcare Data Analyst, Chisquare Labs, IndiaDept. of Pharmacy Practice, Al Shifa College of Pharmacy, IndiaBackground: Monoclonal antibodies have gained attention in developing countries owing to its benefits portrayed by few clinical trials. However, no studies until now have been undergone in India. Methods: A retro-prospective comparative observational study was conducted in symptomatic COVID19 patients to evaluate the impact of Casirivimab and Imdevimab antibody cocktail in the high-risk population. Through an extensive data retrieval for 6 months, 152 samples were documented and sorted into test (Casirivimab and Imdevimab treated patients, n = 79) and control (Non- Casirivimab and Imdevimab treated individuals, n = 73) subsets. The research had two phases; first, estimation of mechanical ventilation and high flow oxygen requirement and mortality in samples amidst the treatment, and second was the post COVID19 patients' feedback through validated (Cronbach's alpha coefficient = 0.7) questionnaire that evaluated their health and vaccination status, and treatment satisfaction. Results: We noticed lesser requisite for mechanical ventilation (6.3%; p < 0.001), high flow oxygen (5.1%; p < 0.001) and no death during Casirivimab and Imdevimab therapy. Meanwhile, non-vaccinated test groups were not on mechanical ventilation and those fully immunized seldom entailed high flow oxygen (test, 6.3%; control, 41.9%, p < 0.01). On evaluating the post COVID19 status of each patient in the study, 90.1% of the test samples were healthy and 97.2% were satisfied with the treatment than those in control group. Conclusions: Casirivimab and Imdevimab regimen was clinically beneficial for high risk COVID19 patients than those treated without the antibody cocktail.http://www.sciencedirect.com/science/article/pii/S2213398422000070COVID19CasirivimabImdevimabMortalityMonoclonal antibody cocktailPost-COVID patient Feedback |
| spellingShingle | Aneesh Puthiyedath Joy Anitha Theresa Augustine Mohammed Salim Karattuthodi Jaffer Chalil Parambil Dilip Chandrasekher P. Danisha Linu Mohan Panakkal Madhav A. Joshi K.T. Azharul Haque Irshad K. Mohammed Izudheen Shadia Badaruddeen Riya Sara John Sarath Murali Ardhra Rose Thomas Fathimath Sahla Shahir Ahmed KV. Ahmed Unni Raseel Omar Ahmed Shinu Cholamugath The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India Clinical Epidemiology and Global Health COVID19 Casirivimab Imdevimab Mortality Monoclonal antibody cocktail Post-COVID patient Feedback |
| title | The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India |
| title_full | The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India |
| title_fullStr | The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India |
| title_full_unstemmed | The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India |
| title_short | The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India |
| title_sort | impact of casirivimab imdevimab antibody cocktail in patients amidst and post covid 19 treatment a retro prospective comparative study in india |
| topic | COVID19 Casirivimab Imdevimab Mortality Monoclonal antibody cocktail Post-COVID patient Feedback |
| url | http://www.sciencedirect.com/science/article/pii/S2213398422000070 |
| work_keys_str_mv | AT aneeshputhiyedathjoy theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT anithatheresaaugustine theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT mohammedsalimkarattuthodi theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT jafferchalilparambil theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT dilipchandrasekher theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT pdanisha theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT linumohanpanakkal theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT madhavajoshi theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT ktazharulhaque theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT irshadkmohammedizudheen theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT shadiabadaruddeen theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT riyasarajohn theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT sarathmurali theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT ardhrarosethomas theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT fathimathsahla theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT shahirahmedkvahmedunni theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT raseelomarahmed theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT shinucholamugath theimpactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT aneeshputhiyedathjoy impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT anithatheresaaugustine impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT mohammedsalimkarattuthodi impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT jafferchalilparambil impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT dilipchandrasekher impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT pdanisha impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT linumohanpanakkal impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT madhavajoshi impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT ktazharulhaque impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT irshadkmohammedizudheen impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT shadiabadaruddeen impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT riyasarajohn impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT sarathmurali impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT ardhrarosethomas impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT fathimathsahla impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT shahirahmedkvahmedunni impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT raseelomarahmed impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia AT shinucholamugath impactofcasirivimabimdevimabantibodycocktailinpatientsamidstandpostcovid19treatmentaretroprospectivecomparativestudyinindia |